GREGORY R HOOK

Summary

Publications

  1. ncbi request reprint Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeutics
    Gregory Hook
    American Life Science Pharmaceuticals Inc, San Diego, CA 92121, USA
    Biol Chem 388:979-83. 2007
  2. doi request reprint The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity
    Gregory Hook
    American Life Science Pharmaceuticals, San Diego, CA 92109, USA
    J Alzheimers Dis 26:387-408. 2011

Collaborators

Detail Information

Publications2

  1. ncbi request reprint Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeutics
    Gregory Hook
    American Life Science Pharmaceuticals Inc, San Diego, CA 92121, USA
    Biol Chem 388:979-83. 2007
    ..The results suggest that cysteine protease inhibitors generally, and reversible cysteine protease inhibitors specifically, have potential for development as AD therapeutics...
  2. doi request reprint The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity
    Gregory Hook
    American Life Science Pharmaceuticals, San Diego, CA 92109, USA
    J Alzheimers Dis 26:387-408. 2011
    ..We conclude that E64d likely reduces brain Aβ by inhibiting cathepsin B and not BACE1 β-secretase activity and that E64d therefore may have potential for treating AD patients...

Research Grants5

  1. Beta-Secretase Assays to Discover Drugs for Alzheimer's
    Gregory Hook; Fiscal Year: 2004
    ..ActiveSite Biotech is in a position to exclusively sell, license, or partner lead drug inhibitors resulting from the Phase II study. ..
  2. Gamma Secretase Assays to Discover Drugs for Alzheimer's
    Gregory Hook; Fiscal Year: 2006
    ..Results will likely identify novel lead compounds for future pre-clinical animal studies for development of effective drugs for AD. ..
  3. Inhibitors of beta-Amyloid Production in Alzheimer's
    Gregory Hook; Fiscal Year: 2007
    ..Specifically, we will assess the affects of these peptidomimetics on beta-amyloid secretion in primary neuronal cultures and in vivo. ..